Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 689-695 , August 2008

[11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer

  • Murat Tuncel

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universität München, 81675 Munich, Germany
    • ,
  • Michael Souvatzoglou

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universität München, 81675 Munich, Germany
    • ,
  • Ken Herrmann

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universität München, 81675 Munich, Germany
    • ,
  • Jens Stollfuss

      Affiliations

    • Department of Radiology, Technische Universität München, 81675 Munich, Germany
    • ,
  • Tibor Schuster

      Affiliations

    • Department of Statistics, Technische Universität München, 81675 Munich, Germany
    • ,
  • Gregor Weirich

      Affiliations

    • Department of Pathology, Technische Universität München, 81675 Munich, Germany
    • ,
  • Hans-Jürgen Wester

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universität München, 81675 Munich, Germany
    • ,
  • Markus Schwaiger

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universität München, 81675 Munich, Germany
    • ,
  • Bernd J. Krause

      Affiliations

    • Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universität München, 81675 Munich, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 89 4140 2961; fax: +49 89 4140 4950.

Received 1 April 2008 ,Revised 6 May 2008 ,Accepted 21 May 2008.

References 

  1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253–8261
  2. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211–216
  3. Donohue RE, Mani JH, Whitesel JA, Mohr S, Scanavino D, Augspurger RR, et al. Pelvic lymph node dissection. Guide to patient management in clinically locally confined adenocarcinoma of prostate. Urology. 1982;20:559–565
  4. Bruce AW, O'Cleireachain F, Morales A, Awad SA. Carcinoma of the prostate: a critical look at staging. J Urol. 1977;117:319–322
  5. Campbell SC, Klein EA, Levin HS, Piedmonte MR. Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology. 1995;46:352–355
  6. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, et al. Should Gleason score 7 prostate cancer be considered a unique grade category?. Urology. 1999;53:372–377
  7. Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term follow-up. J Urol. 1999;161:505–508
  8. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA. 1997;277:467–471
  9. Krämer S, Görich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N, et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol. 1997;70:995–999
  10. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004;231:379–385
  11. Akin O, Hricak H. Imaging of prostate cancer. Radiol Clin North Am. 2007;45:207–222
  12. Huncharek M, Muscat J. Serum prostate specific antigen as a serum marker of bone metastasis in patients with prostate cancer. Urol Int. 1996;156:169–172
  13. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med. 1995;22:207–211
  14. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 1993;269:57–60
  15. Savelli G, Maffioli L, Maccauro M, Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37
  16. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511–1520[electronic publication 2007 Jan 23]
  17. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423–429
  18. Husarik DB, Mirabell R, Dubs M, John H, Giger OT, Gelet A, et al Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2007;35:253–263
  19. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786–793
  20. Reske SN, Blumstein NM, Glatting G. [11C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9–17
  21. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23
  22. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415–1419
  23. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–1340
  24. Hara T. 11C-Choline and 2-deoxy-2-[18F]fluoro-d-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol. 2002;4:267–273
  25. Picchio M, Landoni C, Messa C, Gianolli L, Matarrese M, De Cobelli F, et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol. 2002;179:482–484
  26. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65–72
  27. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200–1209
  28. Metser U, Lerman H, Blank A, Lievshitz G, Bokstein F, Even-Sapir E. Malignant involvement of the spine: assessment by 18F-FDG PET/CT. J Nucl Med. 2004;45:279–284
  29. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F fluoride PET/CT. J Nucl Med. 2004;45:272–278
  30. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. Positron emission tomography with [11C]acetate and [18F]FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607–611
  31. Shimazaki J, Higa T, Akimoto S, Masai M, Isaka S. Clinical course of bone metastasis from prostatic cancer following endocrine therapy: examination with bone x-ray. Adv Exp Med Biol. 1992;324:269–275
  32. Israel O, Goldberg A, Nachtigal A, Militianu D, Bar-Shalom R, Keidar Z, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006;33:1280–1284
  33. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate. 2005;65:178–187
  34. Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V, et al. Value of integrated PET/CT for lesion localization in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging. 2004;31:932–939
  35. Cohade C, Osman M, Leal J, B A, Wahl RL. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–1803
  36. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology. 2005;237:1038–1045

PII: S0969-8051(08)00114-5

doi: 10.1016/j.nucmedbio.2008.05.006

Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 689-695 , August 2008

Article Tools

* Image Usage & Resolution